Performance of IRBs in China: a survey on IRB employees and researchers’ experiences and perceptions

Author:

Liu Xing,Wu Ying,Yang Min,Li Yang,Khoshnood Kaveh,Luo Esther,Li Lun,Wang Xiaomin

Abstract

Abstract Background Performance evaluation is vital for IRB operations. As the number of IRBs and their responsibilities in reviewing and supervising clinical research grow in China, there is a significant need to evaluate their performances. To date, little research has examined IRB performance within China. The aim of this study was to ascertain the perspectives and experiences of IRB employees and researchers to (1) understand the current status of IRBs; (2) compare collected results with those of other countries; and (3) identify shortcomings to improve IRB performance. Methods This study was conducted in China from October 2020 to September 2021, using an online survey with the IRB-researcher assessment tool-Chinese version. Results 757 respondents were included in the analysis and classified into IRB employees, researchers, or those who are both IRB employees and researchers. Overall, the score for an ideal IRB was significantly higher than that of an actual IRB. Compared to the US National Validation study, Chinese participants and American participants both agree and differ in their perspectives on the most and least important ideal items. Conclusion This investigation provides a benchmark of the perceived performance of actual IRBs in China. IRBs in China can be precisely adjusted by targeting identified areas of weakness to improve their performances.

Funder

Major Scientifc and Technological Projects for Collaborative Prevention and Control of Birth Defects in Hunan Province

NIH Fogarty International Center Masters Level Bioethics Program at Central South University in Changsha, China

Publisher

Springer Science and Business Media LLC

Subject

Health Policy,Health (social science),Issues, ethics and legal aspects

Reference53 articles.

1. World Health Organization. Standards and operational guidance for ethics review of health-related research with human participants. World Health Organization. 2011. https://apps.who.int/iris/handle/10665/44783. Accessed 21 Feb 2022.

2. ICH Harmonised Tripartite Guideline for Good Clinical Practice E6(R1). International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. 2016. http://www.ich.org/products/guidelines/efficacy/article/efficacy-guidelines.html. Accessed 21 Feb 2022.

3. Enfield KB, Truwit JD. The Purpose, Composition, and Function of an Institutional Review Board: Balancing Priorities, vol. 53. Respiratory care. Dallas, TX: Daedalus Enterprises;2008, p. 1330–6.

4. Huanhuan C, Li M, Wang M, Roder D, Olver I. Challenges for ethics committees in biomedical research governance: illustrations from China and Australia. J Med Ethics History Med. 2021;2022;14:25–25.

5. Heimer CA, Petty J. Bureaucratic ethics: IRBs and the legal regulation of human subjects research. Annu Rev Law Soc Sci. 2010;6(1):601–26.

Cited by 3 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3